Edition:
United Kingdom

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

570JPY
6:00am GMT
Change (% chg)

¥18 (+3.26%)
Prev Close
¥552
Open
¥553
Day's High
¥574
Day's Low
¥549
Volume
6,262,000
Avg. Vol
6,848,230
52-wk High
¥938
52-wk Low
¥172

Latest Key Developments (Source: Significant Developments)

GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - GNI Group Ltd <2160.T>:Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA.  Full Article

GNI Group gets IND clearance by FDA for liver fibrosis treatment
Monday, 9 Oct 2017 

Oct 9 (Reuters) - GNI Group Ltd <2160.T>:GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis.‍GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017​.‍GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018​.Preliminary results are expected within 2018​.  Full Article

GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis
Monday, 2 Oct 2017 

Oct 2(Reuters) - GNI Group Ltd <2160.T>:Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis.  Full Article

GNI Group announces exercise of options
Thursday, 25 May 2017 

May 25(Reuters) - GNI Group Ltd <2160.T>:Says 2,536 of its 40th series options were exercised to 2.5 million shares, during period from May 9 to May 25.  Full Article

GNI Group gets approval for clinical trial in China for drug of diabetic nephropathy
Wednesday, 17 Aug 2016 

GNI Group Ltd <2160.T>:Says it received approval from China Food and Drug Administration for a pulmonary fibrosis treatment drug's effect on diabetic nephropathy.  Full Article

GNI Group unit gets manufacture and marketing approval of Etuary® in China
Wednesday, 3 Aug 2016 

GNI Group Ltd <2160.T>:Says its unit Beijing Continent Pharmaceuticals Co., Ltd. obtained the manufacture and marketing approval of Etuary® for the treatment of idiopathic pulmonary fibrosis in China.  Full Article

GNI Group subsidiary to set up subsidiary
Monday, 28 Mar 2016 

GNI Group Ltd:Says subsidiary GNI-EPS (HONG KONG) HOLDINGS LIMITED to set up a subsidiary in Shanghai, named GNI-EPS (SHANGHAI) PHARMACEUTICALS, INC.Says GNI-EPS (SHANGHAI) PHARMACEUTICALS, INC with registered capital of 10 mln yuan.  Full Article

GNI Group applies clinical trial permission in U.S
Monday, 14 Mar 2016 

GNI Group Ltd:Says applied clinical trial permission in U.S on March 11 to FDA for liver fiber medicine disease treatment F351.  Full Article

BRIEF-GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product

* Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA